Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 39 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Isatuximab in addition to carfilzomib and dexamethasone for relapsed and/or refractory multiple myeloma	Carfilzomib (Kyprolis; ONO-7057) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2019	View \| Download
Isatuximab in Addition to Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma	Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) , Pomalidomide (Imnovid; CC-4047; Pomalyst)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2018	View \| Download
Isatuximab induction therapy with bortezomib, lenalidomide and dexamethasone for previously untreated multiple myeloma	Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) , Lenalidomide (Revlimid)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2023	View \| Download
Ixazomib Citrate for Newly Diagnosed Multiple Myeloma – maintenance therapy following autologous stem cell transplant	Ixazomib (Ninlaro; MLN 9708; MLN 2238; ixazomib citrate)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2018	View \| Download
Ixazomib citrate for newly diagnosed multiple myeloma inelgible for autologous stem cell transplant– maintenance therapy	Ixazomib (Ninlaro; MLN 9708; MLN 2238; ixazomib citrate)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2019	View \| Download
JNJ-68284528 for relapsed or refractory multiple myeloma	Ciltacabtagene Autoleucel (JNJ-68284528; LCAR-B38M CAR-T cell therapy; LCAR-B38M; JNJ 4528)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2020	View \| Download
Lenalidomide (Revlimid) for Newly Diagnosed Multiple Myeloma – First Line	Lenalidomide (Revlimid)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2017	View \| Download
Melphalan flufenamide in combination with dexamethasone for treating adult patients with relapsed or refractory multiple myeloma	Dexamethasone (dexamethasone sodium metasulfobenzoate) , Melphalan flufenamide hydrochloride (Ygalo; Mel-flufen; J-1)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2020	View \| Download
Phelinun for reduced intensity conditioning treatment prior to allogeneic haematopoietic stem cell transplantation	Melphalan hydrochloride (Cydex; CDX-353; Phelinun)	Acute myeloid leukaemia (AML) , Hodgkin lymphoma , Multiple myeloma (MM) , Neuroblastoma , Non-Hodgkin lymphoma (NHL) , Ovarian cancer	Female Reproductive Cancer , Haematological Cancer and Lymphomas , Neurological Cancer	2021	View \| Download
Pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory multiple myeloma‐ second line and beyond	Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Pomalidomide (Imnovid; CC-4047; Pomalyst)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2017	View \| Download